Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Dec;39(12):2689–2691. doi: 10.1128/aac.39.12.2689

In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species.

J A Vazquez 1, M Lynch 1, J D Sobel 1
PMCID: PMC163013  PMID: 8593003

Abstract

The activity of a new water-soluble pneumocandin, L-733,560, was evaluated with 107 pathogenic strains of Candida and Torulopsis, which included 23 strains with known multi-azole resistance patterns. In vitro evaluation of L-733,560 activity was performed by a broth microdilution method, and the activity was compared with the activities of amphotericin B, fluconazole, ketoconazole, itraconazole, and flucytosine. The mean MICs of L-733,560 were 0.15 microgram/ml for C. lusitaniae, 0.72 microgram/ml for C. parapsilosis, 0.78 micrograms/ml for C. krusei, and 1.25 micrograms/ml for C. guilliermondii. The results indicate that the new antifungal agent L-733,560 demonstrated the best activity with the lowest MICs against C. albicans, T. glabrata, C. tropicalis, and C. kefyr, less activity against C. krusei, C. lusitaniae, and C. parapsilosis, and the least activity against C. guilliermondii. L-733,560 also demonstrated good activity against the various multi-azole-resistant Candida and T. glabrata isolates.

Full Text

The Full Text of this article is available as a PDF (217.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banerjee S. N., Emori T. G., Culver D. H., Gaynes R. P., Jarvis W. R., Horan T., Edwards J. R., Tolson J., Henderson T., Martone W. J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3. [DOI] [PubMed] [Google Scholar]
  2. Beck-Sagué C., Jarvis W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993 May;167(5):1247–1251. doi: 10.1093/infdis/167.5.1247. [DOI] [PubMed] [Google Scholar]
  3. Bodey G. P. Candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):13–19. [PubMed] [Google Scholar]
  4. Bouffard F. A., Zambias R. A., Dropinski J. F., Balkovec J. M., Hammond M. L., Abruzzo G. K., Bartizal K. F., Marrinan J. A., Kurtz M. B., McFadden D. C. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem. 1994 Jan 21;37(2):222–225. doi: 10.1021/jm00028a003. [DOI] [PubMed] [Google Scholar]
  5. Cabib E., Kang M. S. Fungal 1,3-beta-glucan synthase. Methods Enzymol. 1987;138:637–642. doi: 10.1016/0076-6879(87)38057-7. [DOI] [PubMed] [Google Scholar]
  6. Cassone A., Mason R. E., Kerridge D. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. Sabouraudia. 1981 Jun;19(2):97–110. [PubMed] [Google Scholar]
  7. Conly J., Rennie R., Johnson J., Farah S., Hellman L. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis. 1992 Apr;165(4):761–764. doi: 10.1093/infdis/165.4.761. [DOI] [PubMed] [Google Scholar]
  8. Dick J. D., Merz W. G., Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980 Jul;18(1):158–163. doi: 10.1128/aac.18.1.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Espinel-Ingroff A., Kish C. W., Jr, Kerkering T. M., Fromtling R. A., Bartizal K., Galgiani J. N., Villareal K., Pfaller M. A., Gerarden T., Rinaldi M. G. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1992 Dec;30(12):3138–3145. doi: 10.1128/jcm.30.12.3138-3145.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gelfand M. S. Candida tropicalis. Infect Control Hosp Epidemiol. 1989 Jun;10(6):280–283. doi: 10.1086/646024. [DOI] [PubMed] [Google Scholar]
  11. Hickey W. F., Sommerville L. H., Schoen F. J. Disseminated Candida glabrata: report of a uniquely severe infection and a literature review. Am J Clin Pathol. 1983 Nov;80(5):724–727. doi: 10.1093/ajcp/80.5.724. [DOI] [PubMed] [Google Scholar]
  12. Horn R., Wong B., Kiehn T. E., Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985 Sep-Oct;7(5):646–655. doi: 10.1093/clinids/7.5.646. [DOI] [PubMed] [Google Scholar]
  13. Komshian S. V., Uwaydah A. K., Sobel J. D., Crane L. R. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989 May-Jun;11(3):379–390. doi: 10.1093/clinids/11.3.379. [DOI] [PubMed] [Google Scholar]
  14. Nobre G., Mendes E., Charrua M. J., Cruz O. Ketoconazole resistance in Torulopsis glabrata. Mycopathologia. 1989 Jul;107(1):51–55. doi: 10.1007/BF00437589. [DOI] [PubMed] [Google Scholar]
  15. Powderly W. G., Kobayashi G. S., Herzig G. P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988 May;84(5):826–832. doi: 10.1016/0002-9343(88)90059-9. [DOI] [PubMed] [Google Scholar]
  16. Sanchez V., Vazquez J. A., Barth-Jones D., Dembry L., Sobel J. D., Zervos M. J. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol. 1992 Nov;30(11):3005–3008. doi: 10.1128/jcm.30.11.3005-3008.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sanchez V., Vazquez J. A., Barth-Jones D., Dembry L., Sobel J. D., Zervos M. J. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med. 1993 Jun;94(6):577–582. doi: 10.1016/0002-9343(93)90207-6. [DOI] [PubMed] [Google Scholar]
  18. Sawistowska-Schröder E. T., Kerridge D., Perry H. Echinocandin inhibition of 1,3-beta-D-glucan synthase from Candida albicans. FEBS Lett. 1984 Jul 23;173(1):134–138. doi: 10.1016/0014-5793(84)81032-7. [DOI] [PubMed] [Google Scholar]
  19. States B., Segal S. Levels of gamma-glutamyltranspeptidase in cultured skin fibroblasts from cystinotics and normals. Life Sci. 1980 Nov 24;27(21):1985–1990. doi: 10.1016/0024-3205(80)90419-1. [DOI] [PubMed] [Google Scholar]
  20. Warnock D. W., Burke J., Cope N. J., Johnson E. M., von Fraunhofer N. A., Williams E. W. Fluconazole resistance in Candida glabrata. Lancet. 1988 Dec 3;2(8623):1310–1310. doi: 10.1016/s0140-6736(88)92919-4. [DOI] [PubMed] [Google Scholar]
  21. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]
  22. Woods R. A., Bard M., Jackson I. E., Drutz D. J. Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J Infect Dis. 1974 Jan;129(1):53–58. doi: 10.1093/infdis/129.1.53. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES